Back to top

Image: Bigstock

Surging Earnings Estimates Signal Upside for Fullgent Genetics (FLGT) Stock

Read MoreHide Full Article

Investors might want to bet on Fullgent Genetics (FLGT - Free Report) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook.

Analysts' growing optimism on the earnings prospects of this company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. This insight is at the core of our stock rating tool -- the Zacks Rank.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

For Fullgent Genetics, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year.

Current-Quarter Estimate Revisions

For the current quarter, the company is expected to earn $2.56 per share, which is a change of -58.71% from the year-ago reported number.

The Zacks Consensus Estimate for Fullgent Genetics has increased 35.45% over the last 30 days, as one estimate has gone higher compared to no negative revisions.

Current-Year Estimate Revisions

The company is expected to earn $15.58 per share for the full year, which represents a change of +71.21% from the prior-year number.

There has been an encouraging trend in estimate revisions for the current year as well. Over the past month, one estimate has moved up for Fullgent Genetics versus no negative revisions. This has pushed the consensus estimate 26.67% higher.

Favorable Zacks Rank

The promising estimate revisions have helped Fullgent Genetics earn a Zacks Rank #1 (Strong Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom Line

Fullgent Genetics shares have added 10.3% over the past four weeks, suggesting that investors are betting on its impressive estimate revisions. So, you may consider adding it to your portfolio right away to benefit from its earnings growth prospects.


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Fulgent Genetics, Inc. (FLGT) - free report >>

Published in